Skip to main content

Table 6 Key Findings for the influence of designated Strategic Health Authority/Health Board of treatment and access to chemotherapy

From: A systematic review of geographical variation in access to chemotherapy

Study Un-adjusted OR (CI) Adjusted OR for receipt of chemotherapy (CI) P-value
Cartman ‘02 [35] The proportion of patients having chemotherapy was 9.5 % (range 5 % to 12.9 %) Adjusted analysis performed for survival regression analysis only Not performed
Jack ‘03 [37] Median % and range of chemo-therapy by health authority: chemo-therapy alone: 4 %, range 3-9 %, any chemo-therapy median 8 %, range 4-17 %. Odds of chemotherapy if first hospital visited was a radiotherapy centre: OR 1.38 (1.06 to 1.80). P = 0.018
Paterson ‘13 [42] Unadjusted OR not given Health board A, OR 1.00 (0.89, 1.38) (of any chemotherapy), Health board B OR 1.11 (0.89 to 1.38) P 0.36, Health board C OR 1.07, (0.91 to 1.25) Health Board B 0.36
Health Board C 0.42
Stephens ‘12 [33] From figure. Not performed Not performed
Everolimus 0.2 to 2.1 mg per head pre CDF across five SHAs reduced to 0.55 to 1.45 post-CDF; Lapatinib 0.05 to 2.0 pre-CDF and 0.70 to 1.25 after; Sorafenib 0.08 to 2.5 pre-CDF and 0.45 to 1.3 after; Bevacizumab and Cetuximab 0.25 to 2.1 pre and 0.45 to 2.0 post-CDF.